Oncology
Navigating the Complexities of Cancer Care
Winning in the World's Most Competitive Therapeutic Area
Oncology is the most dynamic and competitive segment in the pharmaceutical industry, with over 1,500 molecules in active clinical development globally. Asset values are high, windows of competitive advantage are narrow, and the pace of scientific advancement — from checkpoint inhibitors to ADCs and CAR-T — demands continuous intelligence to protect and grow market position.
Our oncology competitive intelligence maps the full competitive landscape across solid tumours and haematologic malignancies. We track pipeline progression, clinical trial designs and endpoints, regulatory submissions, commercial launch strategies, and the shifting role of biomarkers and companion diagnostics. We help you anticipate competitor moves before they become market realities.
What We Analyse
What You Will Receive
Competitive Landscape Report
Full mapping of approved, late-stage, and emerging competitors across your target indication with strategic commentary.
Pipeline Intelligence Tracker
Ongoing monitoring of competitor clinical milestones, trial recruitments, and regulatory submissions.
KOL Sentiment Analysis
Qualitative synthesis of scientific advisory board feedback, congress presentations, and published opinion.
Launch Strategy Benchmarking
How top-5 recent oncology launches were executed: pricing, sequencing, patient support, and access strategy.
Who This Intelligence Is For
- Oncology commercial and medical affairs teams
- Clinical and regulatory strategy leaders in pharma and biotech
- Licensing and business development executives
- Oncology-focused investors and venture capital funds
Ready to gain an edge?
Connect with our team to discuss how our Oncology intelligence can support your strategic objectives.
Schedule a Consultation